THURSDAY, SEPTEMBER 29, 2016

Researchers findperamivir effective against influenza if used quickly

Researchers announced on Saturday that an analysis of phase II and III clinical trials of the neuraminidase inhibitor peramivir is effective at alleviating influenza symptoms when administered within 48 hours of the onset of symptoms.

The scientists made the announcement at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious diseases meeting of the American Society for Microbiology in Washington, D.C., ScienceDaily reports.

"Based on clinical data, peramivir is the first neuraminidase inhibitor that has shown to be safe and effective as a single-dose therapy for patients with acute, uncomplicated influenza," Rich Whitley, a professor at the University of Alabama at Birmingham and the presenting author of the study, said, according to ScienceDaily. "According to a retrospective combined analysis of two clinical studies, a single dose of peramivir, administered intramuscularly, alleviated flu symptoms, including fever, significantly faster than the studies' placebo arms."

The two placebo-controlled studies examined a total of 427 patients.

Peramivir has been approved in Japan and Korea since 2010. Approximately one million Japanese patients have used the treatment since its approval, ScienceDaily reports.

Influenza is responsible for more than 200,000 hospitalizations and 36,000 deaths in the U.S. every year, according to the Centers for Disease Control and Prevention.